Sun Pharma Q4 Profit Rises 26% on Specialty Drug Growth; Jubilant Pharmova Reports Mixed Q4 Results
2 hours agoBusiness
29LENS
15 SourcesMumbai, India
TBNthebalanced.news

Sun Pharma Q4 Profit Rises 26% on Specialty Drug Growth; Jubilant Pharmova Reports Mixed Q4 Results

Sun Pharmaceutical Industries reported a 26% year-on-year rise in consolidated net profit to Rs 2,714 crore for Q4 FY26, with revenue increasing about 13% to Rs 14,612 crore. Growth was driven by strong performance in India formulations and specialty medicines, while US sales declined slightly due to generics weakness. EBITDA rose 6.4% but margins narrowed. For FY26, net profit grew 5% to Rs 11,479 crore, with revenue up 12%. The company announced a final dividend of Rs 5 per share and projects slower, high single-digit growth for FY27 amid regulatory and macroeconomic challenges. Jubilant Pharmova reported mixed results with Q4 revenue up 5% but net profit down 21%, impacted by exceptional items.

Political Bias
0%100%0%
Sentiment
66%
AI analysis of 13 sources · Published under editorial oversight by The Balanced News
Analysed 22 May 2026· How this analysis is produced· Editorial standards· Corrections

AI Analysis

Political bias across 15 sources
● Left 0%● Center 100%● Right 0%

The article group primarily presents corporate financial results with a focus on business performance and market factors. Coverage includes company statements and analyst perspectives without partisan framing. Both positive growth and challenges are reported, reflecting a business-centric viewpoint rather than political angles. The inclusion of multiple companies and balanced reporting of gains and declines indicates a neutral economic perspective.

Sentiment — Positive (66/100)

The overall tone is mixed-positive, highlighting strong profit and revenue growth for Sun Pharma alongside challenges such as US market softness and margin contraction. Jubilant Pharmova's results introduce a more cautious note with profit declines. The sentiment balances optimism about specialty medicines and innovation with acknowledgment of regulatory and market headwinds, maintaining an informative and measured tone.

How 13 sources covered this story

Each source's own headline, political lean, and sentiment — so you can see framing differences at a glance.

SourceTheir headlineBiasSentiment
businessstandardSun Pharma Q4 PAT jumps 26 YoY to Rs 2,714 crCenterPositive
businessstandardJubilant Pharmova consolidated net profit declines 22.27 in the March 2026 quarterCenterNeutral
businessstandardSun Pharmaceutical Industries consolidated net profit rises 26.24 in the March 2026 quarterCenterPositive
businessstandardSun Pharma US: Challenging year for Sun Pharma in US as FY26 revenue falls 0.9CenterNeutral
thefinancialexpressSun Pharma Q4 profit rises 26 to Rs 2,714 crore, revenue grows 13 , dividend announcedCenterPositive
news18Jubilant Pharmova Q4 profit declines 21 pc at Rs 119.3 crCenterNeutral
news18Sun Pharma Q4 net profit rises 26.2 pc at Rs 2,714.03 crCenterPositive
businessstandardSun Pharma posts Q4 profit of 2,714 crore on strong specialty drug demandCenterPositive
freepressjournalSun Pharma Reports 14 Revenue Growth To 14,612 Crore, Net Profit Up 26 In Q4CenterPositive
freepressjournalJubilant Pharmova Reports 5.1 Revenue Growth To 1,804 Crore, Net Profit Up 11 In Q4CenterPositive
economictimesSun Pharma Q4 Results: Cons profit rises 26 YoY to Rs 2,714 crore; board approves Rs 5 share dividendCenterNeutral
mintSun Pharma Q4 results 2026: Profit jumps 26 YoY to 2,714 crore; recommends final dividend of 5 for FY26 Stock Market NewsCenterPositive
economictimesSun Pharma Q4 Preview: Can Unloxcyt and speciality drugs help pharma major deliver another strong quarter?CenterPositive

Coverage timeline

economictimes broke this story on 21 May, 10:32 am. Other outlets followed.

  1. 1
    economictimes21 May, 10:32 am
    Sun Pharma Q4 Preview: Can Unloxcyt and speciality drugs help pharma major deliver another strong quarter?
  2. 2
    mint22 May, 09:36 am
    Sun Pharma Q4 results 2026: Profit jumps 26 YoY to 2,714 crore; recommends final dividend of 5 for FY26 Stock Market News
  3. 3
    economictimes22 May, 09:44 am
    Sun Pharma Q4 Results: Cons profit rises 26 YoY to Rs 2,714 crore; board approves Rs 5 share dividend
  4. 4
    freepressjournal22 May, 09:44 am
    Jubilant Pharmova Reports 5.1 Revenue Growth To 1,804 Crore, Net Profit Up 11 In Q4
  5. 5
    freepressjournal22 May, 10:00 am
    Sun Pharma Reports 14 Revenue Growth To 14,612 Crore, Net Profit Up 26 In Q4
  6. 6
    businessstandard22 May, 10:03 am
    Sun Pharma posts Q4 profit of 2,714 crore on strong specialty drug demand
  7. 7
    news1822 May, 10:13 am
    Sun Pharma Q4 net profit rises 26.2 pc at Rs 2,714.03 cr
  8. 8
    news1822 May, 10:55 am
    Jubilant Pharmova Q4 profit declines 21 pc at Rs 119.3 cr
  9. 9
    thefinancialexpress22 May, 11:01 am
    Sun Pharma Q4 profit rises 26 to Rs 2,714 crore, revenue grows 13 , dividend announced
  10. 10
    businessstandard22 May, 12:34 pm
    Sun Pharma US: Challenging year for Sun Pharma in US as FY26 revenue falls 0.9

Lens Score breakdown

29/100
Public interest0/100
Coverage gap80%

Well-covered story — coverage matches public importance.

Who's involved

Institutions and figures named across source coverage.

Corporate
Organon CoCheckpoint TherapeuticsSun Pharmaceutical IndustriesJubilant BiosysSun PharmaJubilant PharmovaSun Pharmaceuticals

Story context

Category
Business
Location
Mumbai, India
Sources analysed
15
Last analysed
22 May 2026
Key entities
CroreIndian rupeeSun PharmaNet incomeIndiaDividendFiscal yearPharmaceutical industryChief executive officerEarnings before interest, taxes, depreciation, and amortizationEquity (finance)Generic drug